Peanut Allergy

CTAF

ICER will assess the comparative clinical effectiveness and value of treatments for peanut allergy. This evidence review will examine two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT). Viaskin® Peanut is currently undergoing FDA review with an approval decision expected in mid-2019, and Aimmune Therapeutics has filed their application with the FDA for approval of AR101, with a decision expected by August 2019. This list is tentative and subject to change.

Associated Meetings

June 11, 2019 10AM-4PM

California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA 94612

CTAF will convene to review ICER's assessment of treatments for peanut allergy.


Key Dates

Associated Materials

11/20/2018

11/20/2018

11/20/2018 – 12/12/2018

12/20/2018

04/09/2019
Draft Evidence Report

04/09/2019 – 05/08/2019
Public Comments

05/28/2019
Evidence Report

05/28/2019
Response to Comments

06/11/2019
Evidence Presentation

07/03/2019
Final Evidence Report and Meeting Summary